Final antigenic Melan-A peptides produced directly by the proteasomes are preferentially selected for presentation by HLA-A*0201 in melanoma cells.

Détails

ID Serval
serval:BIB_CE2DAEC4B472
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Final antigenic Melan-A peptides produced directly by the proteasomes are preferentially selected for presentation by HLA-A*0201 in melanoma cells.
Périodique
Journal of Immunology
Auteur⸱e⸱s
Chapatte L., Servis C., Valmori D., Burlet-Schiltz O., Dayer J., Monsarrat B., Romero P., Lévy F.
ISSN
0022-1767[print], 0022-1767[linking]
Statut éditorial
Publié
Date de publication
2004
Volume
173
Numéro
10
Pages
6033-6040
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Résumé
The melanoma-associated protein Melan-A contains the immunodominant CTL epitope Melan-A(26/27-35)/HLA-A*0201 against which a high frequency of T lymphocytes has been detected in many melanoma patients. In this study we show that the in vitro degradation of a polypeptide encompassing Melan-A(26/27-35) by proteasomes produces both the final antigenic peptide and N-terminally extended intermediates. When human melanoma cells expressing the corresponding fragments were exposed to specific CTL, those expressing the minimal antigenic sequence were recognized more efficiently than those expressing the N-terminally extended intermediates. Using a tumor-reactive CTL clone, we confirmed that the recognition of melanoma cells expressing an N-terminally extended intermediate of Melan-A is inefficient. We demonstrated that the inefficient cytosolic trimming of N-terminally extended intermediates could offer a selective advantage for the preferred presentation of Melan-A peptides directly produced by the proteasomes. These results imply that both the proteasomes and postproteasomal peptidases limit the availability of antigenic peptides and that the efficiency of presentation may be affected by conditions that alter the ratio between fully and partially processed proteasomal products.
Mots-clé
Amino Acid Sequence, Animals, Antigen Presentation/genetics, Antigen Presentation/immunology, Antigens, Neoplasm/biosynthesis, Antigens, Neoplasm/genetics, Cell Line, Cell Line, Tumor, Cytosol/enzymology, Epitopes, T-Lymphocyte/genetics, Epitopes, T-Lymphocyte/metabolism, HLA-A Antigens/biosynthesis, HLA-A Antigens/metabolism, Humans, Hydrolysis, Intracellular Fluid/enzymology, Melanoma/immunology, Melanoma/metabolism, Mice, Molecular Sequence Data, Neoplasm Proteins/biosynthesis, Neoplasm Proteins/genetics, Peptide Fragments/biosynthesis, Peptide Fragments/genetics, Peptide Hydrolases/metabolism, Proteasome Endopeptidase Complex/immunology, Proteasome Endopeptidase Complex/metabolism, Protein Precursors/genetics, Protein Precursors/metabolism, Protein Processing, Post-Translational/genetics, Protein Processing, Post-Translational/immunology, T-Lymphocytes, Cytotoxic/enzymology, T-Lymphocytes, Cytotoxic/immunology
Pubmed
Web of science
Création de la notice
28/01/2008 11:17
Dernière modification de la notice
20/08/2019 15:48
Données d'usage